Jinzhuo Fan1, Renxian Liang2. 1. Department of Traditional Chinese Medicine and Acupuncture, Hainan Hospital of General Hospital of Chinese PLA, Sanya, China. 2. Department of Cardiovascular and Endocrinology, Beibei Traditional Chinese Medicine Hospital, Chongqing, China.
Abstract
BACKGROUND: Numerous studies have evaluated the association between TLR4 gene polymorphisms and T2DM risk. However, the findings were inconsistent and controversial. METHODS: In order to drive a more precise estimation, we carried out a meta-analysis based on 41 studies involving 23,250 cases and 24,760 controls. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of association. RESULTS: Our meta-analysis provides evidence that rs4986790 polymorphism was associated with an increased risk of T2DM in Asian (AG vs. AA, OR = 1.23, 95% CI = 1.01-1.50, p = 0.042; G vs. A, OR = 1.21, 95% CI = 1.01-1.44, p = 0.041). Rs4986791 polymorphism was related to an increased risk of T2DM both in Asian (AG vs. AA, OR = 1.76, 95% CI = 1.11-2.80, p = 0.017; G vs. A, OR = 1.63, 95% CI = 1.04-2.55, p = 0.034) and Caucasian (GG vs. AA, OR = 2.42, 95% CI = 1.23-4.75, p = 0.010). Rs11536889 polymorphism may have a protective effect on T2DM in Chinese populations (CC vs. GG, OR = 0.62, 95% CI = 0.40-0.96, p = 0.031; GC vs. GG, OR = 0.77, 95% CI = 0.61-0.98, p = 0.034; CC vs. GC/GG, OR = 0.81, 95% CI = 0.69-0.96, p = 0.013; C vs. G, OR = 0.76, 95% CI = 0.59-0.97, p = 0.027), whereas rs1927911 may have no impact. CONCLUSIONS: These findings supported that rs4986790, rs4986791, and rs11536889 may contribute to the risk of T2DM.
BACKGROUND: Numerous studies have evaluated the association between TLR4 gene polymorphisms and T2DM risk. However, the findings were inconsistent and controversial. METHODS: In order to drive a more precise estimation, we carried out a meta-analysis based on 41 studies involving 23,250 cases and 24,760 controls. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated to assess the strength of association. RESULTS: Our meta-analysis provides evidence that rs4986790 polymorphism was associated with an increased risk of T2DM in Asian (AG vs. AA, OR = 1.23, 95% CI = 1.01-1.50, p = 0.042; G vs. A, OR = 1.21, 95% CI = 1.01-1.44, p = 0.041). Rs4986791 polymorphism was related to an increased risk of T2DM both in Asian (AG vs. AA, OR = 1.76, 95% CI = 1.11-2.80, p = 0.017; G vs. A, OR = 1.63, 95% CI = 1.04-2.55, p = 0.034) and Caucasian (GG vs. AA, OR = 2.42, 95% CI = 1.23-4.75, p = 0.010). Rs11536889 polymorphism may have a protective effect on T2DM in Chinese populations (CC vs. GG, OR = 0.62, 95% CI = 0.40-0.96, p = 0.031; GC vs. GG, OR = 0.77, 95% CI = 0.61-0.98, p = 0.034; CC vs. GC/GG, OR = 0.81, 95% CI = 0.69-0.96, p = 0.013; C vs. G, OR = 0.76, 95% CI = 0.59-0.97, p = 0.027), whereas rs1927911 may have no impact. CONCLUSIONS: These findings supported that rs4986790, rs4986791, and rs11536889 may contribute to the risk of T2DM.
Authors: Marcel A M Beijk; S Matthijs Boekholdt; Saskia Z H Rittersma; Douwe Pons; Aeilko H Zwinderman; Pieter A F Doevendans; Rene A Tio; Jan G P Tijssen; J Wouter Jukema; Robbert J de Winter Journal: Pharmacogenet Genomics Date: 2010-09 Impact factor: 2.089
Authors: N H Cho; J E Shaw; S Karuranga; Y Huang; J D da Rocha Fernandes; A W Ohlrogge; B Malanda Journal: Diabetes Res Clin Pract Date: 2018-02-26 Impact factor: 5.602
Authors: J Hernesniemi; T Lehtimäki; R Rontu; M S Islam; C Eklund; J Mikkelsson; E Ilveskoski; O Kajander; S Goebeler; L E Viiri; M Hurme; P J Karhunen Journal: Scand J Clin Lab Invest Date: 2006 Impact factor: 1.713
Authors: C S Aioanei; R F Ilies; C Bala; M F Petrisor; M D Porojan; R A Popp; A Catana Journal: Acta Endocrinol (Buchar) Date: 2019 Jan-Mar Impact factor: 0.877